News >

FDA Grants Pembrolizumab/Lenvatinib Breakthrough Designation for RCC

Jason M. Broderick @jasoncology
Published: Tuesday, Jan 09, 2018

Dr. Roy Baynes

Roy Baynes, MD, PhD
The FDA has granted the combination of the PD-1 inhibitor pembrolizumab (Keytruda) and the VEGF/FGF inhibitor lenvatinib (Lenvima) a breakthrough therapy designation for the treatment of patients with advanced and/or metastatic renal cell carcinoma (RCC).

ORR at 24 weeks was 83% (95% CI, 52-98) in the treatment-naïve cohort, and 50% in those patients who received previous treatment. All responses were partial responses. Two patients in the treatment-naïve group and 8 in the previously-treated population had stable disease. One patient in each cohort had primary progressive disease.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication